DE102005055128A1 - Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor - Google Patents

Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor Download PDF

Info

Publication number
DE102005055128A1
DE102005055128A1 DE102005055128A DE102005055128A DE102005055128A1 DE 102005055128 A1 DE102005055128 A1 DE 102005055128A1 DE 102005055128 A DE102005055128 A DE 102005055128A DE 102005055128 A DE102005055128 A DE 102005055128A DE 102005055128 A1 DE102005055128 A1 DE 102005055128A1
Authority
DE
Germany
Prior art keywords
vector
pharmaceutical agents
relates
treatment
hepatocellular carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE102005055128A
Other languages
English (en)
Other versions
DE102005055128B4 (de
Inventor
Brigitte Puetzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Rostock
Original Assignee
Universitaet Rostock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Rostock filed Critical Universitaet Rostock
Priority to DE102005055128.9A priority Critical patent/DE102005055128B4/de
Priority to PCT/EP2006/068374 priority patent/WO2007057368A1/de
Publication of DE102005055128A1 publication Critical patent/DE102005055128A1/de
Application granted granted Critical
Publication of DE102005055128B4 publication Critical patent/DE102005055128B4/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft einen viralen Vektor, der Nukleinsäure-Sequenzen umfasst, die IL-12 und ein Kostimulator-Protein kodieren und ferner einen AFP-Promotor und MER-I-Enhancer umfassen. Die Erfindung betrifft insbesondere einen tricistronischen adenoviralen Vektor, der IL-12p40, IL-12p35 und B7.1 co-exprimiert. Gegenstand der Erfindung ist auch die Verwendung des Vektors zur Therapie von Leberzellkarzinomen, vorzugsweise von hepatozellulären Karzinomen. Die Erfindung betrifft auch pharmazeutische Mittel, die den Vektor oder Viruspartikel umfassen.
DE102005055128.9A 2005-11-15 2005-11-15 Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor Expired - Fee Related DE102005055128B4 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE102005055128.9A DE102005055128B4 (de) 2005-11-15 2005-11-15 Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
PCT/EP2006/068374 WO2007057368A1 (de) 2005-11-15 2006-11-13 Viraler vektor, dessen verwendung zur therapie von leberzellkarzinomen und pharmazeutische mittel umfassend den vektor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005055128.9A DE102005055128B4 (de) 2005-11-15 2005-11-15 Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor

Publications (2)

Publication Number Publication Date
DE102005055128A1 true DE102005055128A1 (de) 2007-05-16
DE102005055128B4 DE102005055128B4 (de) 2015-04-02

Family

ID=37744169

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102005055128.9A Expired - Fee Related DE102005055128B4 (de) 2005-11-15 2005-11-15 Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor

Country Status (2)

Country Link
DE (1) DE102005055128B4 (de)
WO (1) WO2007057368A1 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013085624A1 (en) * 2011-12-08 2013-06-13 Virovek, Inc. Vectors harboring toxic genes, methods and uses therefor
US10124028B2 (en) 2015-04-30 2018-11-13 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein or active fragment
CN109642240A (zh) * 2015-12-18 2019-04-16 昂科赛克医疗公司 异源蛋白质表达的质粒构造和使用方法
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
US11439678B2 (en) 2013-10-25 2022-09-13 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
US11840702B2 (en) 2017-08-28 2023-12-12 Akamis Bio Limited Adenovirus armed with bispecific T cell activator

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
GB201907493D0 (en) * 2019-05-28 2019-07-10 Ospedale San Raffaele Agents and methods for treating viral infections
CN111850041A (zh) * 2020-07-30 2020-10-30 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的含il12双顺反子的病毒构建体及其用途和构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104621A1 (en) * 1993-11-04 2003-06-05 Taiki Tamaoki Method of expressing genes in mammalian cells
US6585968B2 (en) * 1997-03-03 2003-07-01 Cell Genesys, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
DE10248141A1 (de) * 2002-10-11 2004-09-02 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020010206A (ko) * 2000-07-27 2002-02-04 이시우 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104621A1 (en) * 1993-11-04 2003-06-05 Taiki Tamaoki Method of expressing genes in mammalian cells
US6585968B2 (en) * 1997-03-03 2003-07-01 Cell Genesys, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
DE10248141A1 (de) * 2002-10-11 2004-09-02 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013085624A1 (en) * 2011-12-08 2013-06-13 Virovek, Inc. Vectors harboring toxic genes, methods and uses therefor
US11938159B2 (en) 2013-10-25 2024-03-26 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
US11439678B2 (en) 2013-10-25 2022-09-13 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
US10548929B2 (en) 2015-04-30 2020-02-04 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a therapeutic protein or active fragment
US10849945B2 (en) 2015-04-30 2020-12-01 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein or active fragment
US10322152B2 (en) 2015-04-30 2019-06-18 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
US10124028B2 (en) 2015-04-30 2018-11-13 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein or active fragment
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
US11970536B2 (en) 2015-12-17 2024-04-30 Akamis Bio Limited Group B adenovirus encoding an anti-TCR-complex antibody or fragment
CN109642240A (zh) * 2015-12-18 2019-04-16 昂科赛克医疗公司 异源蛋白质表达的质粒构造和使用方法
US11713467B2 (en) 2015-12-18 2023-08-01 Oncosec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
US11840702B2 (en) 2017-08-28 2023-12-12 Akamis Bio Limited Adenovirus armed with bispecific T cell activator

Also Published As

Publication number Publication date
WO2007057368A1 (de) 2007-05-24
DE102005055128B4 (de) 2015-04-02

Similar Documents

Publication Publication Date Title
DE102005055128A1 (de) Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
TR200500221T2 (tr) Farmasötik Maddeler Olarak Bisiklik Amino Asitler
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
PL371736A1 (en) Method for administering glp-1 molecules
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2003045316A3 (en) Polynucleotide therapy
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
ATE534635T1 (de) N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
DE60132190D1 (de) Mutierte version der arginin deiminase
NO20076405L (no) Anvendelse av 24-nor-UDCA
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
DE50200711D1 (de) Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
WO2004005540A3 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen
WO2004089982A3 (en) April variants and methods thereof
ATE480630T1 (de) Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
R016 Response to examination communication
R016 Response to examination communication
R018 Grant decision by examination section/examining division
R020 Patent grant now final
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee